NZ586859A - Drug delivery system for administration of poorly water soluble pharmaceutically active substances - Google Patents

Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Info

Publication number
NZ586859A
NZ586859A NZ586859A NZ58685908A NZ586859A NZ 586859 A NZ586859 A NZ 586859A NZ 586859 A NZ586859 A NZ 586859A NZ 58685908 A NZ58685908 A NZ 58685908A NZ 586859 A NZ586859 A NZ 586859A
Authority
NZ
New Zealand
Prior art keywords
methyl ester
sodium salt
cysteic acid
delivery system
drug delivery
Prior art date
Application number
NZ586859A
Other languages
English (en)
Inventor
Julian Aleksov
Igor Lokot
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ586859(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of NZ586859A publication Critical patent/NZ586859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ586859A 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances NZ586859A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
PCT/SE2008/051515 WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (1)

Publication Number Publication Date
NZ586859A true NZ586859A (en) 2012-06-29

Family

ID=40795732

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586859A NZ586859A (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Country Status (27)

Country Link
US (4) US8999382B2 (enExample)
EP (1) EP2231189B1 (enExample)
JP (1) JP5466172B2 (enExample)
KR (1) KR101572703B1 (enExample)
CN (1) CN101951956B (enExample)
AU (1) AU2008339099B2 (enExample)
BR (1) BRPI0821740B1 (enExample)
CA (1) CA2709266C (enExample)
CY (2) CY1119805T1 (enExample)
DK (1) DK2231189T3 (enExample)
EA (1) EA015247B1 (enExample)
ES (1) ES2650242T3 (enExample)
FR (1) FR19C1030I1 (enExample)
HR (1) HRP20171796T1 (enExample)
HU (1) HUE034684T2 (enExample)
LT (2) LT2231189T (enExample)
LU (1) LUC00117I2 (enExample)
MX (1) MX2010006914A (enExample)
MY (2) MY157187A (enExample)
NL (1) NL300987I9 (enExample)
NO (2) NO2231189T3 (enExample)
NZ (1) NZ586859A (enExample)
PL (1) PL2231189T3 (enExample)
PT (1) PT2231189T (enExample)
SI (1) SI2231189T1 (enExample)
WO (2) WO2009078754A1 (enExample)
ZA (1) ZA201004685B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
AU2010239689A1 (en) * 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer
CN115429886B (zh) * 2021-06-02 2025-10-31 复旦大学 一种药物纳米结晶制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
CN100360502C (zh) * 2002-07-23 2008-01-09 阿登尼亚投资有限公司 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US20050196343A1 (en) 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2009078755A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Also Published As

Publication number Publication date
HUE034684T2 (en) 2018-02-28
JP2011507838A (ja) 2011-03-10
BRPI0821740B1 (pt) 2021-05-18
CN101951956B (zh) 2012-10-17
SI2231189T1 (en) 2018-03-30
EP2231189A4 (en) 2013-10-09
US20110014281A1 (en) 2011-01-20
JP5466172B2 (ja) 2014-04-09
FR19C1030I1 (fr) 2019-06-21
BRPI0821740A2 (pt) 2020-02-27
ES2650242T3 (es) 2018-01-17
NO2019023I1 (no) 2019-05-08
EA200802350A2 (ru) 2009-06-30
NO2231189T3 (enExample) 2018-02-03
LT2231189T (lt) 2017-12-27
NL300987I2 (enExample) 2019-05-09
US9993438B2 (en) 2018-06-12
CY2019021I2 (el) 2019-11-27
US20150164819A1 (en) 2015-06-18
NL300987I9 (nl) 2019-05-16
LTPA2019508I1 (lt) 2019-05-10
WO2009078802A1 (en) 2009-06-25
CY2019021I1 (el) 2019-11-27
CY1119805T1 (el) 2018-06-27
MX2010006914A (es) 2010-11-10
WO2009078754A1 (en) 2009-06-25
CA2709266A1 (en) 2009-06-25
CN101951956A (zh) 2011-01-19
PT2231189T (pt) 2017-12-12
USRE49742E1 (en) 2023-12-05
MY157186A (en) 2016-05-13
AU2008339099A1 (en) 2009-06-25
EA015247B1 (ru) 2011-06-30
DK2231189T3 (en) 2017-12-11
EP2231189B1 (en) 2017-09-06
CA2709266C (en) 2017-09-26
KR20100094575A (ko) 2010-08-26
EP2231189A1 (en) 2010-09-29
USRE49741E1 (en) 2023-12-05
PL2231189T3 (pl) 2018-03-30
MY157187A (en) 2016-05-13
HRP20171796T1 (hr) 2018-01-26
ZA201004685B (en) 2011-03-30
AU2008339099B2 (en) 2015-08-13
EA200802350A3 (ru) 2009-10-30
LUC00117I2 (enExample) 2024-05-22
US8999382B2 (en) 2015-04-07
KR101572703B1 (ko) 2015-11-27

Similar Documents

Publication Publication Date Title
USRE49742E1 (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
RU2451510C2 (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
CN101291658B (zh) 用于制备稳定性增加的水难溶性药物的组合物和方法
JP2017114913A (ja) ナノ粒子処方物およびその使用
JP2011517683A (ja) 疎水性タキサン誘導体の組成物およびその使用
CN101945670B (zh) 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统
US8324274B2 (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
CN101209251A (zh) 含有紫杉醇或多烯紫杉醇的弹性纳米囊泡制剂及其制备方法
CN112121028B (zh) 一种辛伐他汀固体纳米粒制剂及其制备方法
US20230364026A1 (en) Stabilized solid nanoparticle formulations of cannabinoids and cannabinoid analogs with reduced ostwald ripening for oral, inhalation, nasal and parenteral drug delivery
RU2522977C2 (ru) Композиции и способы доставки фармакологических агентов
UA96273C2 (uk) Композиція доцетакселу і цитрату для лікування раку

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2016 BY LEA SKYLLERSTEDT

Effective date: 20151210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2017 BY CPA GLOBAL (PATRAFEE)

Effective date: 20161208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2018 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2020 BY CPA GLOBAL (STOCKHOLM)

Effective date: 20191204

ASS Change of ownership

Owner name: OASMIA PHARMACEUTICAL AB, SE

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20201125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2022 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20211120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2023 BY ACUMASS

Effective date: 20221118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2024 BY ACUMASS

Effective date: 20231121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2025 BY OLIVIER BARLOY

Effective date: 20241120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2026 BY ACUMASS

Effective date: 20251120